Trevi Therapeutics
TRVI
20 hedge funds and large institutions have $63.5M invested in Trevi Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 18 → 20 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.32% less ownership
Funds ownership: 79.44% → 79.12% (-0.32%)
40% less capital invested
Capital invested by funds: $106M → $63.5M (-$42.8M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$176K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$134K |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$62.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.21K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$5.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$357K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$215K |
| 3 |
Millennium Management
New York
|
-$92K |
| 4 |
Morgan Stanley
New York
|
-$30.1K |
| 5 |
BlackRock
New York
|
-$12.6K |
TRVI Hedge Fund Activity: Q3 2019 in Review
20 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2019, worth a combined $63.5M — down 40% from $106M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRVI positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $176K. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $357K.
- 20 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2019, up from 18 in Q2 2019.
- Funds reported $63.5M of Trevi Therapeutics stock for Q3 2019, down 40% quarter-over-quarter.
- 4 funds opened new Trevi Therapeutics positions in Q3 2019 and 2 closed out, a net change of +2 holders.
- The largest Trevi Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $176K added.
- The largest Trevi Therapeutics seller in Q3 2019 was Schonfeld Strategic Advisors, an estimated $357K sold.
Based on aggregated 13F filings for Q3 2019.